Neogen vs RxSight
Neogen reported revenue of $870 million in fiscal 2026, 6.5 times RxSight's $134 million in fiscal 2025. Neogen's revenue fell 2.7% in its latest year, and RxSight's fell 3.9%. Neogen had an operating margin of -2.5%, against -35.8% at RxSight. Free cash flow was $32 million at Neogen and −$19 million at RxSight. Their fiscal years end in different months (May 31 and December 31), so the periods don't line up exactly.
Side by side
| Neogen | RxSight | |
|---|---|---|
| Latest fiscal year | FY2026, May 31, 2026 | FY2025, Dec 31, 2025 |
| Revenue | $870M | $134M |
| Revenue growth | −2.7% | −3.9% |
| Revenue growth a year, last 5 years | 13.2% | 55.7% |
| Gross margin | 46.9% | 76.6% |
| Operating margin | −2.5% | −35.8% |
| Net margin | −0.9% | −29.0% |
| Free cash flow | $32M | −$19M |
| Free cash flow margin | 3.7% | −14.4% |
| Return on capital | −0.6% | −82.9% |
| Net debt to EBITDA | 6.4x | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 0.3% | 5.1% |
| Last close | $10.85 | $4.61 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $6,386, sold $114,676 | sold $103,745 |
| Piotroski F-score | 5 of 9 | 3 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
NeogenRxSight
Operating margin
Percent of revenue
NeogenRxSight
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
NeogenRxSight